JNJ-4496 Prevents Antigen Escape, May Work as Salvage Therapy in R/R LBCL

Commentary
Video

Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.

Patients who have progressed following treatment with CD19 chimeric antigen receptor (CAR) T-cell therapy may benefit from subsequent treatment with JNJ-90014496 (JNJ-4496), an investigational CD19/CD20-targeted CAR T-cell therapy, according to Matthew Ku, MBBS, PhD, FRACP, RACP, FRCPA/RCPA.

Ku, a clinical and laboratory hematologist and lymphoma stream lead at St Vincent’s Private Hospital, Fitzroy in Australia, spoke with CancerNetwork® about how JNJ-4496 may improve clinical outcomes vs other CAR T-cell therapies used to manage relapsed/refractory large B-cell lymphoma (LBCL).

He initially suggested that despite CD19 CAR T-cell therapy enhancing outcomes for patients with the disease, the long-term remission rate is still wanting, with less than 50% achieving it. Highlighting antigen escape via loss of CD19 on the lymphoma cell surface as a primary concern, he explained that JNJ-4496 was specifically designed to prevent antigen escape with the potential to serve as a salvage therapy. Furthermore, he concluded by expressing the potential for the investigational agent to replace CD19 CAR T-cell therapy as a second-line option altogether, given the potential for enhanced efficacy outcomes.

Results from a small cohort of patients (n = 25) enrolled in a phase 1b study (NCT05421663) he presented at the European Hematology Association 2025 Congress revealed that for patients treated with the recommended phase 2 dose (RP2D) of 75 million CAR T cells, the objective response rate (ORR) was 96% (95% CI, 77%-100%), with 77% of patients achieving a complete response (CR).

Among patients given the RP2D previously treated with 1 prior line of therapy, the ORR was 100% (95% CI, 69%-100%), with 80% of patients achieving a CR. In the same patient group previously treated with 2 or more prior lines of therapy, the ORR was 92% (95% CI, 62%-100%), with 75% of patients attaining a CR.

Transcript:

CD19 CAR [T-cell] therapy has been good at transforming the treatment landscape for patients with relapsed/refractory large B-cell lymphoma. Despite that, less than 50% of patients achieve long-term remission. Antigen escape with the loss of CD19 on the lymphoma cell surface is one of the major issues. With a CD19/CD20 bispecific CAR T, it is designed to prevent antigen escape as a mechanism for resistance and possibly [work as] a salvage therapy.

If you have a patient who has had CD19 CAR [T-cell therapy] and progressed from that, then this could be a salvage option after that. In the future, perhaps this would be shown to be superior [vs] the CD19 CAR [T-cell therapy] and therefore even replace single CD19 CAR T as a second-line therapy in the future.

Reference

Patel K, Rhodes JM, Mountjoy L, et al. A global phase 1b study of JNJ-90014496, a CD19/CD20 bi-specific chimeric antigen receptor (CAR) T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma. Abstract presented at: European Hematology Association 2025 Congress; June 12-15, 2025; Milan, Italy. Abstract S239.

Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
Related Content